Skip to main content
Premium Trial:

Request an Annual Quote

High Throughput Genomics Raises $10M in First Tranche of Series C Round

NEW YORK (GenomeWeb News) — High Throughput Genomics has pocketed $10 million in a first tranche of Series C financing, the Tucson, Ariz.-based company said yesterday.
 
HTG, which provides microplate-based gene expression assay technology and services to drug makers, said it will use the cash to expand research and product development efforts in the areas of molecular diagnostics and proteomics, and to build out its commercialization team.
 
HTG's qNPA technology is used in quantitative, multiplexed, gene-based drug-discovery programs, including target validation, high-throughput screening lead optimization, metabolism, toxicology, and clinical development.
 
According to the company, its ArrayPlate lysis-only qNPA platform enables scientists to test any sample, including fixed tissues, while avoiding the need for extraction or target amplification.
 
The financing came from three existing and one new venture capital investor. Leading the tranche was Merck Capital Ventures, with additional investments coming from Solstice Capital, Valley Ventures, and Arcturus Capital, a first-time stakeholder in HTG.
 
As part of the deal, Solstice Capital’s managing partner, Harry George, will become HTG’s chairman. George has been a member of HTG's board since 2002.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.